 |
|
Osteoporosis drug Fosamax linked to heart problem
April 29, 2008Finding from Group Health and University of Washington study
SEATTLE-Women who have used Fosamax are nearly twice as likely to develop the most common kind of chronically irregular heartbeat (atrial fibrillation) than are those who have never used it, according to research from Group Health and the University of Washington published in the April 28 Archives of Internal Medicine.
Merck markets Fosamax, the most widely used drug treatment for the bone-thinning disease osteoporosis, explained study leader Susan Heckbert, MD, PhD, MPH, a professor of epidemiology and scientific investigator in the Cardiovascular Health Research Unit at the University of Washington. The Food and Drug Administration (FDA) approved the first generic versions (called alendronate) in February.
"We studied more than 700 female Group Health patients whose atrial fibrillation was first detected during a three-year period," said Dr. Heckbert. She and her colleagues compared those women to over 900 randomly selected female Group Health members matched on age and high blood pressure to serve as controls.
"Having ever used alendronate was associated with an 86 percent higher risk of newly detected atrial fibrillation compared with never having used the drug," said Dr. Heckbert, who is also an affiliate investigator at the Group Health Center for Health Studies.
Osteoporosis mostly affects older women and can set the stage for fractures that can impair the quality of their lives, said Dr. Heckbert. "Careful judgment is required to weigh the risks and benefits of any medication for any individual patient," she added. "For most women at high risk of fracture, alendronate's benefit of reducing fractures will outweigh the risk of atrial fibrillation."
However, said Dr. Heckbert, "women who are at high risk of fractures but also have risk factors for atrial fibrillation-such as heart failure, diabetes, or coronary disease-might want to discuss alternatives to alendronate with their health care providers." Other medications that can lower the risk of fractures include estrogen, she said. But the Women's Health Initiative, on which she has also served as an investigator, showed other heart risks from hormone therapy combining estrogen with progesterone.
The National Heart, Lung, and Blood Institute funds Dr. Heckbert's Atrial Fibrillation Study, which collects data on all Group Health patients as they are first diagnosed with atrial fibrillation. The study aims to find new factors that raise the risk of developing this quivering of the heart's upper chambers (atria).
About one in 100 people-and nearly nine in 100 people over age 80-have atrial fibrillation, said Dr. Heckbert. In many cases, atrial fibrillation has no symptoms, and it isn't necessarily life threatening. But it can cause palpitations, fainting, fatigue, or congestive heart failure.
Atrial fibrillation can also make blood pool-and sometimes clot-in the atria, said Dr. Heckbert. When parts of clots break off and leave the atria, they can lead to embolic strokes, as happens in over 70,000 Americans a year. That's why atrial fibrillation is often treated with the anticoagulant warfarin. Other results from her study have suggested that maintaining a healthy body weight may help protect people from atrial fibrillation.
"This study will help medical teams better inform their patients about the risks associated with Fosamax, helping us make the best treatment decisions for managing osteoporosis," commented Christine Himes Fordyce, MD, a Group Health family practitioner. "Now with this increased understanding of potential irregular heartbeats, both physicians and their patients should be alert to any problems, report them immediately, and treat them appropriately."
Group Health Cooperative Center for Health Studies
"We studied more than 700 female Group Health patients whose atrial fibrillation was first detected during a three-year period," said Dr. Heckbert. She and her colleagues compared those women to over 900 randomly selected female Group Health members matched on age and high blood pressure to serve as controls.
"Having ever used alendronate was associated with an 86 percent higher risk of newly detected atrial fibrillation compared with never having used the drug," said Dr. Heckbert, who is also an affiliate investigator at the Group Health Center for Health Studies.
Osteoporosis mostly affects older women and can set the stage for fractures that can impair the quality of their lives, said Dr. Heckbert. "Careful judgment is required to weigh the risks and benefits of any medication for any individual patient," she added. "For most women at high risk of fracture, alendronate's benefit of reducing fractures will outweigh the risk of atrial fibrillation."
However, said Dr. Heckbert, "women who are at high risk of fractures but also have risk factors for atrial fibrillation-such as heart failure, diabetes, or coronary disease-might want to discuss alternatives to alendronate with their health care providers." Other medications that can lower the risk of fractures include estrogen, she said. But the Women's Health Initiative, on which she has also served as an investigator, showed other heart risks from hormone therapy combining estrogen with progesterone.
The National Heart, Lung, and Blood Institute funds Dr. Heckbert's Atrial Fibrillation Study, which collects data on all Group Health patients as they are first diagnosed with atrial fibrillation. The study aims to find new factors that raise the risk of developing this quivering of the heart's upper chambers (atria).
About one in 100 people-and nearly nine in 100 people over age 80-have atrial fibrillation, said Dr. Heckbert. In many cases, atrial fibrillation has no symptoms, and it isn't necessarily life threatening. But it can cause palpitations, fainting, fatigue, or congestive heart failure.
Atrial fibrillation can also make blood pool-and sometimes clot-in the atria, said Dr. Heckbert. When parts of clots break off and leave the atria, they can lead to embolic strokes, as happens in over 70,000 Americans a year. That's why atrial fibrillation is often treated with the anticoagulant warfarin. Other results from her study have suggested that maintaining a healthy body weight may help protect people from atrial fibrillation.
"This study will help medical teams better inform their patients about the risks associated with Fosamax, helping us make the best treatment decisions for managing osteoporosis," commented Christine Himes Fordyce, MD, a Group Health family practitioner. "Now with this increased understanding of potential irregular heartbeats, both physicians and their patients should be alert to any problems, report them immediately, and treat them appropriately."
Group Health Cooperative Center for Health Studies
Atrial Fibrillation Current Events and Atrial Fibrillation News RSSStudy provides insight on a common heart rhythm disorder
University of Iowa researchers and colleagues in France have identified a gene variant that causes a potentially fatal human heart rhythm disorder called sinus node disease.
Novel Imaging Approach May Assist in Predicting Success of Treatment For Atrial Fibrillation
University of Utah researchers have developed a magnetic resonance imaging (MRI)-based method for detecting and quantifying injury to the wall of the heart's left atrium in patients who have undergone a procedure to treat atrial fibrillation.
Blood thinning drug linked to increased bleeding in brain
A new study shows that people who take the commonly used blood thinning drug warfarin may have larger amounts of bleeding in the brain and increased risk of death if they suffer a hemorrhagic stroke.
Best use of drug-eluting stents
Compared with bare metal stents, drug-eluting stents substantially reduce the risk of angiographic and clinical recurrence but do not affect mortality or the short term or long term risk of myocardial infarction.
First human use of new device to make arrhythmia treatment safer
On June 16, 2008, Barbara Ganschow of Palatine, IL, became the first person in the world to be successfully treated with a new device designed to make it safer and easier for heart specialists to create a hole in the cardiac atrial septum.
Mayo Clinic spearheads research to discover unsuspected gene for atrial fibrillation
Mayo Clinic researchers have found a gene mutation linked to one family's hereditary form of atrial fibrillation. Researchers hope this discovery will lead to better understanding of the disease and, eventually, better ways to predict, prevent and treat the heart rhythm problem.
The Montreal Heart Institute presents findings on congestive heart failure and atrial fibrillation
The results of a major international clinical trial coordinated by the Montreal Heart Institute were reported today in the New England Journal of Medicine.
Computers as safe as medical experts for prescribing blood thinning drugs
The largest ever study into the administration of blood thinning drugs, principally Warfarin, has concluded that dosages calculated by computer are at least as safe and reliable as those provided by expert medical professionals.
Study finds that obstructive sleep apnea causes earlier death in stroke patients
Stroke victims who have obstructive sleep apnea die sooner than stroke victims who do not have sleep apnea or who have central sleep apnea, according to Swedish researchers.
Mitochondrial dysfunction and redox signaling in atrial tachyarrhythmia
Researchers at the University Hospital of Magdeburg (Germany) have discovered that atrial tachycardia is associated with mitochondrial dysfunction and oxidative stress followed by the activation of the NF-kB signalling pathway with induction of NF-kB target gene expression in atrial tissue.
More Atrial Fibrillation Current Events and Atrial Fibrillation News Articles
 | Atrial Fibrillation (Fundamental and Clinical Cardiology) Filling a gap in the literature, this all-encompassing reference explores the epidemiology, mechanisms, and pathophysiology of atrial fibrillation and compiles the latest diagnostic and treatment practices for patient care. The book summarizes the most recent advances in symptom relief, drug development, device management, and long-term control of heart rhythm abnormalities and reviews the... |
 | Atrial Fibrillation : My Heart, the Doctors, and Me by E. A. Butler An Investigative Report by an Inquisitive Patient The author felt compelled to write this story after discovering he had paroxysmal atrial fibrillation. He had little previous experience with personal illnesses. Now he found himself dealing with production line medicine. This experience fostered skepticism, doubts, apprehensions and grave concerns. He discovered he was afflicted with ... |
 | Atrial Fibrillation: From Bench to Bedside (Contemporary Cardiology) Advancements in the treatment and prevention of Atrial Fibrillation are presented in this important new book. Atrial Fibrillation affects approximately 2.5 million individuals in the United States and is projected to affect 15 million individuals by 2050. In Atrial Fibrillation: From Bench to Bedside, the reader is provided with the latest information that is critically important in the daily... |
 | Catheter Ablation of Atrial Fibrillation by Etienne, MD Aliot, Michel Haissaguerre, W. Jackman Catheter Ablation of Atrial Fibrillation Edited byEtienne Aliot, MD, FESC, FACC, FHRS Chief of Cardiology, Hôpital Central, University of Nancy, FranceMichel Haïssaguerre, MD Chief of Electrophysiology, Hôpital Cardiologique du Haut-Lévêque, FranceWarren M. Jackman, MD Chief of Electrophysiology, University of Oklahoma Health Science Center, USAIn this text, internationally recognized... |
 | A Practical Approach to Catheter Ablation of Atrial Fibrillation Written and edited by expert electrophysiologists, this book is a practical, well-illustrated guide to the most successful techniques for catheter ablation of atrial fibrillation. While other texts address ablation of different arrhythmias, this is the first book to focus specifically on atrial fibrillation. Chapters explain how to establish programs and laboratories for treating atrial... |
 | Atrial Fibrillation Ablation: The State of the Art based on the Venicechart International Consensus Document by Andrea Natale, Antonio Raviele In recent years, catheter ablation of atrial fibrillation has become a widespread treatment modality in electrophysiology laboratories all over the world. Nevertheless, many aspects of the therapy are controversial.Developed by world-renowned experts in the field, this book presents a comprehensive and up-to date overview of all the most important and debated aspects of atrial fibrillation... |
 | Innovative Management of Atrial Fibrillation Atrial fibrillation is underdiagnosed and preventative strategies are underutilized.The disease is estimated to rise to an epidemic level, increasing by over 50% by the end of the decade, occurring commonly in the setting of otherwise “healthy” aging.Innovative Management of Atrial Fibrillation provides a forum for a full discussion on this topical matter. Distinguished experts from both... |
| Hope emerges on multiple fronts to control atrial fibrillation; new medications and interventions are being developed to stop one of the leading causes ... ablation.: An article from: Heart Advisor by Gale Reference Team This digital document is an article from Heart Advisor, published by Thomson Gale on October 1, 2007. The length of the article is 1064 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation DetailsTitle: Hope emerges... | |
 | Atrial Fibrillation by Johan Waktare, A John Camm Reference handbook for clinicians treating atrial fibrillation (AF) drawing on the experience of the St George's AF Group, detailing new research data, problems in ventricular rate control, new concepts in cardioversion, new approaches to curing AF, and drug therapy, all illustrated with clear, original... |
 | Manual of Surgical Treatment of Atrial Fibrillation In recent years, a myriad of surgical protocols have been developed to manage atrial fibrillation, increasing the confusion over which are the most effective approaches. This timely book presents a multidisciplinary, international team of authorities who have reviewed the evidence in order to establish which surgical approaches should be used under which circumstances.Divided into five parts, the... |
| © 2008 BrightSurf.com |